GLG News Analyses of the following article:

NeuroSearch successfully advances NSD-721 for treatment of social anxiety disorder and receives EUR 5 million in equity financing under the alliance with GlaxoSmithKline

view article

Published at: www.pipelinereview.com

Treatment of Social Anxiety Disorderved

August 6, 2009

GLG Expert Contributor

 NeuroSearch new drug NSD-721 will be of great benefit to patients with Social Anxiety Disorder.

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
9 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software